-
Product Insights
Gaucher Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Gaucher Disease - Drugs In Development, 2023’, provides an overview of the Gaucher Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gaucher Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Gaucher Disease Type I – Drugs In Development, 2023
Global Markets Direct’s, ‘Gaucher Disease Type I - Drugs In Development, 2023’, provides an overview of the Gaucher Disease Type I pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gaucher Disease Type I, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Gaucher Disease Type III – Drugs In Development, 2023
Global Markets Direct’s, ‘Gaucher Disease Type III - Drugs In Development, 2023’, provides an overview of the Gaucher Disease Type III pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gaucher Disease Type III, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Sector Analysis
Gaucher Disease Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Gaucher Disease Market Report Overview The Gaucher Disease market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued $1.22 billion in 2022. A steady growth is anticipated at a CAGR of less than 1% from 2022 to 2032. The major driver for this growth will be improved diagnostic approaches, the launch of Sanofi’s SRT venglustat malate, as well as the introduction of eliglustat tartrate generics. The Gaucher Disease market research report offers an...
-
Product Insights
Gaucher Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Gaucher Disease Clinical Trials Report Overview The Gaucher disease clinical trials report provides an overview of the clinical trials, including top-line data. The data highlights the number of trial numbers and their average enrolment in top countries conducted across the globe. Furthermore, the clinical trials for Gaucher disease are elaborated by region, country (G7 & E7), phase, trial status, end points status, and sponsor type, in this report. Key Regions ·       Asia-Pacific ·       Europe ·       North America ·       Middle East...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.